Patent US2946026A successfully refreshed from Google Patents.
Patent US4664913A successfully refreshed from Google Patents.
US4664913A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for treating plasma for transfusion
Assignee: Xoma Royalty Corp
•
Filing: 1984-07-19
•
Granted: 1987-05-12
•
Expires: 2004-07-19
Abstract
Abstract A method for treating human blood plasma which comprises passing plasma through an immunoadsorbent zone capable of binding both anti-A and anti-B blood group antibodies and removing them from the plasma. Plasma so treated may be transfused to any recipient regardless of the recipient's blood type, and it is found that such treated plasma retains substantially all other blood proteins essential for proper physiological activity.
Inventors
- 👤 C. Harold Mielke
- 👤 Patrick J. Scannon
- 👤 Paul R. Sohmer
- 👤 John C. Klock
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 14:46
CPC Classifications
A; A61; A61M; A61M1/00; A61M1/36; A61M1/3679; A61K; A61K35/00; A61K35/12; A61K35/14; A61K35/16
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
92 words
A method for treating human blood plasma from a donor prior to transfusion to a recipient to prevent ABH blood group incompatibility, regardless of the recipient's blood type, said method employing an immunoadsorbent zone including receptors consisting essentially of receptors specific for both anti-A and anti-B antibodies immobilized therein, said method comprising: passing the plasma through the immunoadsorbent zone so that substantially all of said anti-A and anti-B antibodies are specifically removed from the plasma without reducing the concentrations of blood factors below levels necessary for blood clotting in the transfusion recipient.
Claim 2
Independent Claim
92 words
A method for treating human blood plasma from a donor prior to transfusion to a recipient to prevent ABH blood group incompatibility, regardless of the recipient's blood type, said method employing an immunoadsorbent zone including receptors consisting essentially of receptors specific for both anti-A and anti-B antibodies immobilized therein, said method comprising: passing the plasma through the immunoadsorbent zone so that substantially all of said anti-A and anti-B antibodies are specifically removed from the plasma without reducing the concentrations of blood factors below levels necessary for blood clotting in the transfusion recipient.
Claim 3
Independent Claim
114 words
A method for treating human blood from a donor to produce plasma suitable for transfusion to a recipient having any ABH blood type, said method employing an immunoadsorbent zone including receptor consisting essentially of receptor capable of binding both anti-A and anti-B antibodies, said method comprising: separating substantially all blood cells and platelets from the blood to form plasma; passing the plasma through the immunoadsorbent zone so that substantially all anti-A and anti-B antibodies are removed without reducing the concentrations of blood factors below levels necessary for blood clotting in the transfusion recipient; and collecting the plasma to provide a source of plasma suitable for transfusion to recipients regardless of the recipient's blood group.
Claim 4
Independent Claim
114 words
A method for treating human blood from a donor to produce plasma suitable for transfusion to a recipient having any ABH blood type, said method employing an immunoadsorbent zone including receptor consisting essentially of receptor capable of binding both anti-A and anti-B antibodies, said method comprising: separating substantially all blood cells and platelets from the blood to form plasma; passing the plasma through the immunoadsorbent zone so that substantially all anti-A and anti-B antibodies are removed without reducing the concentrations of blood factors below levels necessary for blood clotting in the transfusion recipient; and collecting the plasma to provide a source of plasma suitable for transfusion to recipients regardless of the recipient's blood group.
Claim 5
Independent Claim
86 words
A method for transfusing plasma from a donor to a recipient, regardless of ABH blood group incompatibility, said method employing an immunoadsorbent zone containing receptor consisting essentially of receptor capable of binding both anti-A and anti-B antibodies, said method comprising: passing the plasma through the immunoadsorbent zone under conditions such that substantially all anti-A and anti-B antibodies are removed from the plasma without reducing the concentrations of blood factors below levels necessary for blood clotting in the transfusion recipient; and transfusing the plasma to a patient.
Claim 6
Independent Claim
86 words
A method for transfusing plasma from a donor to a recipient, regardless of ABH blood group incompatibility, said method employing an immunoadsorbent zone containing receptor consisting essentially of receptor capable of binding both anti-A and anti-B antibodies, said method comprising: passing the plasma through the immunoadsorbent zone under conditions such that substantially all anti-A and anti-B antibodies are removed from the plasma without reducing the concentrations of blood factors below levels necessary for blood clotting in the transfusion recipient; and transfusing the plasma to a patient.
Claim 7
Independent Claim
33 words
A method as in claims 1, 2 or 3, wherein both the anti-A and anti-B antibodies are removed to a concentration undetectable by a standard antiglobulin (Coombs) test at a dilution of 1:2.
Claim 8
Independent Claim
21 words
A method as in claims 1, 2 or 3, wherein the receptor in the immunoadsorbent zone includes A and B antigens.
Claim 9
Independent Claim
21 words
A method as in claims 1, 2 or 3, wherein the receptor in the immunoadsorbent zone includes anti-(anti-A) and anti-(anti-B) antibodies.
Claim 10
Independent Claim
22 words
A method as in claims 1, 2 or 3, wherein the immunoadsorbent zone comprises receptor immobilized on an insoluble, biocompatible solid support.
Claim 11
Independent Claim
20 words
A method as in claims 1, 2 or 3, wherein the immunoadsorbent zone comprises receptors immobilized in a permeable membrane.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-05-11 | 1990-11-10 | 1991-05-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-05-11 | 1994-11-10 | 1995-05-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-05-11 | 1998-11-10 | 1999-05-12 | $7700.00 | Window Closed / Lapsed |